Trevi Therapeutics Inc (TRVI)

Currency in USD
7.320
-0.130(-1.74%)
Closed·
7.3200.000(0.00%)
·
TRVI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TRVI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.2407.455
52 wk Range
2.3608.110
Key Statistics
Prev. Close
7.32
Open
7.4
Day's Range
7.24-7.455
52 wk Range
2.36-8.11
Volume
919.45K
Average Volume (3m)
1.9M
1-Year Change
146.46%
Book Value / Share
1.67
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TRVI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.600
Upside
+181.42%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Trevi Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Trevi Therapeutics Inc Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Trevi Therapeutics Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of -$0.09 beats forecast by 10%, net loss narrows to $12.3M from $12.4M YoY
  • R&D expenses decrease to $9.4M, G&A expenses rise to $4.3M; cash runway extended into 2029
  • Positive chronic cough trial results; Phase III trials planned for H1 2026, FDA meeting by Q4 2025
  • Stock closes at $7.33, up 0.41% after-hours; analysts maintain strong buy consensus
  • CEO highlights strategic progress; management confident in financial position and clinical milestones
Last Updated: 08/08/2025, 11:04
Read Full Transcript

Compare TRVI to Peers and Sector

Metrics to compare
TRVI
Peers
Sector
Relationship
P/E Ratio
−18.8x−0.5x−0.6x
PEG Ratio
2.700.100.00
Price/Book
4.5x2.2x2.6x
Price / LTM Sales
-1.8x3.3x
Upside (Analyst Target)
193.7%173.5%40.1%
Fair Value Upside
Unlock1.6%5.3%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.600
(+181.42% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.09 / -0.10
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TRVI Income Statement

People Also Watch

20.18
SRPT
-3.86%
3.970
ATAI
-1.98%
5.28
REPL
-0.94%
12.25
DYN
-0.65%
49.59
PTCT
-0.42%

FAQ

What Stock Exchange Does Trevi Therapeutics Trade On?

Trevi Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Trevi Therapeutics?

The stock symbol for Trevi Therapeutics is "TRVI."

What Is the Trevi Therapeutics Market Cap?

As of today, Trevi Therapeutics market cap is 889.58M.

What Is Trevi Therapeutics's Earnings Per Share (TTM)?

The Trevi Therapeutics EPS (TTM) is -0.42.

When Is the Next Trevi Therapeutics Earnings Date?

Trevi Therapeutics will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is TRVI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Trevi Therapeutics Stock Split?

Trevi Therapeutics has split 0 times.

How Many Employees Does Trevi Therapeutics Have?

Trevi Therapeutics has 33 employees.

What is the current trading status of Trevi Therapeutics (TRVI)?

As of 20 Aug 2025, Trevi Therapeutics (TRVI) is trading at a price of 7.32, with a previous close of 7.32. The stock has fluctuated within a day range of 7.24 to 7.46, while its 52-week range spans from 2.36 to 8.11.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.